Mifepristone and Misoprostol for 2nd Trimester Termination of Pregnancy in Burkina Faso

• Status: Unknown status
• Trial end date: 2019-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

The goal of this study is to examine the effectiveness and feasibility of a mifepristone-misoprostol medical abortion regimen in terminating pregnancies 13-22 weeks in Burkina Faso.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Gynuity Health Projects
• Treatments: Mifepristone; Misoprostol

Criteria

Inclusion Criteria:

• Having an ongoing pregnancy of 13-22 weeks gestation

• Be willing to undergo surgical completion if necessary

• Have no contraindications to study procedures, according to provider

• Be willing and able to consent to participate in the study

• Be willing to follow study procedures

• Respect legal indications for obtaining an abortion

Exclusion Criteria:

• Known allergy to mifepristone or misoprostol/prostaglandin

• Any contraindications to vaginal delivery, including placenta previa

• Previous transmural uterine incsion